Price Disclosure Reductions for 2023 October Cycle

Page last updated: 25 January 2024

The 2023 October cycle has a data collection period of 1 October 2022 to 31 March 2023.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2023.

The reduction day is 1 October 2023.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Contents

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2023 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2023 will also take the reduction on 1 October 2023 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 14 July 2023.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.

Legal Instrument Drug

Legal Instrument Form

Legal Instrument MoA

Brands of PI designated brands under 99ADHC (Y/N)

Price reduction applied in 2 previous cycles (Y/N?)

Average UPR exceeds 12.5% over 3 cycles (Y/N)

Step 3. Average AEMP (brand)

WAPD (%) (Drug/MoA)

Oct-23 AEMP ($)

Apr-23 AEMP ($)

Percentage difference between Apr-23 and Oct-23 AEMP (%)

UPR threshold (%)

Calculations based on:
OWAPD = all brand data
GWAPD = originator brand data

abacavir with lamivudine

Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg

Oral

Y

Y

Y

63.34

36.38%

40.3

63.34

36.38%

30%

GWAPD

aciclovir

Eye ointment 30 mg per g, 4.5 g

Application to the eye

N

-

-

19.95

29.43%

14.08

17.69

20.41%

10%

OWAPD

arsenic

Injection concentrate containing arsenic trioxide 10 mg in 10 mL

Injection

N

-

-

1241.62

52.92%

584.55

1241.62

52.92%

10%

OWAPD

azacitidine

Powder for injection 100 mg

Injection

Y

Y

Y

59.83

31.83%

40.79

59.83

31.82%

30%

OWAPD

bisacodyl

Tablet 5 mg

Oral

Y

N

Y

5.57

42.37%

4

5.57

42.37%

30%

OWAPD

bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Y

Y

Y

7.65

32.64%

5.15

7.65

32.68%

30%

GWAPD

bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

Y

Y

Y

4.9

32.64%

4

4.9

32.65%

30%

GWAPD

bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Y

Y

Y

6.12

32.64%

4.12

6.12

32.68%

30%

GWAPD

bortezomib

Powder for injection 1 mg

Injection

N

-

-

172.91

56.62%

75.01

129.98

42.29%

10%

OWAPD

bortezomib

Powder for injection 2.5 mg

Injection

N

-

-

432.28

56.62%

187.52

324.94

42.29%

10%

OWAPD

bortezomib

Powder for injection 3.5 mg

Injection

N

-

-

605.17

56.62%

262.52

454.91

42.29%

10%

OWAPD

bortezomib

Solution for injection 2.5 mg in 1 mL

Injection

N

-

-

432.28

56.62%

187.52

324.94

42.29%

10%

OWAPD

bortezomib

Solution for injection 3.5 mg in 1.4 mL

Injection

N

-

-

605.17

56.62%

262.52

454.91

42.29%

10%

OWAPD

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 3 mL

Injection

N

-

-

304.57

49.92%

152.53

178.77

14.68%

10%

OWAPD

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 6 mL

Injection

N

-

-

304.57

49.92%

152.53

178.77

14.68%

10%

OWAPD

capecitabine

Tablet 150 mg

Oral

Y

Y

Y

7.94

31.64%

5.43

7.94

31.61%

30%

OWAPD

capecitabine

Tablet 500 mg

Oral

Y

Y

Y

49.24

31.64%

33.66

49.24

31.64%

30%

OWAPD

carvedilol

Tablet 12.5 mg

Oral

Y

Y

Y

7.65

33.95%

5.05

7.65

33.99%

30%

GWAPD

carvedilol

Tablet 25 mg

Oral

Y

Y

Y

9.56

33.95%

6.31

9.56

34.00%

30%

GWAPD

carvedilol

Tablet 6.25 mg

Oral

Y

Y

Y

6.12

33.95%

4.04

6.12

33.99%

30%

GWAPD

cefepime

Powder for injection 2 g (as hydrochloride)

Injection

Y

Y

Y

5.2

33.43%

4

5.2

33.46%

30%

OWAPD

cefuroxime

Tablet 250 mg (as axetil)

Oral

N

-

-

6.76

22.04%

5.27

6.76

22.04%

10%

GWAPD

ciprofloxacin

Tablet 500 mg (as hydrochloride)

Oral

Y

Y

Y

4.81

31.37%

4

4.81

31.39%

30%

OWAPD

ciprofloxacin

Tablet 750 mg (as hydrochloride)

Oral

Y

Y

Y

7.25

31.37%

4.98

7.25

31.31%

30%

OWAPD

dasatinib

Tablet 100 mg

Oral

N

-

-

3085.89

33.56%

2050.27

2712.5

24.41%

10%

OWAPD

dasatinib

Tablet 20 mg

Oral

N

-

-

1873.54

33.56%

1244.78

1646.84

24.41%

10%

OWAPD

dasatinib

Tablet 50 mg

Oral

N

-

-

3085.89

33.56%

2050.27

2712.5

24.41%

10%

OWAPD

dasatinib

Tablet 70 mg

Oral

N

-

-

3820.54

33.56%

2538.37

3358.25

24.41%

10%

OWAPD

deferasirox

Tablet 180 mg

Oral

N

-

-

146.19

36.49%

92.85

130.48

28.84%

10%

OWAPD

deferasirox

Tablet 360 mg

Oral

N

-

-

292.38

36.49%

185.69

260.96

28.84%

10%

OWAPD

deferasirox

Tablet 90 mg

Oral

N

-

-

73.1

36.49%

46.43

65.24

28.83%

10%

OWAPD

doxorubicin - pegylated liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL

Injection

Y

N

Y

223.44

38.05%

138.42

223.44

38.05%

30%

GWAPD

doxorubicin - pegylated liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL

Injection

Y

N

Y

531.99

38.05%

329.57

531.99

38.05%

30%

GWAPD

everolimus

Tablet 0.25 mg

Oral

N

-

-

191.76

20.77%

151.93

171.18

11.25%

10%

GWAPD

everolimus

Tablet 0.5 mg

Oral

N

-

-

334.74

20.77%

265.21

334.74

20.77%

10%

GWAPD

everolimus

Tablet 0.75 mg

Oral

N

-

-

502.1

20.77%

397.81

502.1

20.77%

10%

GWAPD

everolimus

Tablet 1 mg

Oral

N

-

-

669.47

20.77%

530.42

669.47

20.77%

10%

GWAPD

ezetimibe

Tablet 10 mg

Oral

Y

N

Y

8.28

36.64%

5.25

8.28

36.59%

30%

GWAPD

ezetimibe with atorvastatin

Tablet 10 mg-10 mg

Oral

N

-

-

9.7

12.21%

8.52

9.7

12.16%

10%

GWAPD

ezetimibe with atorvastatin

Tablet 10 mg-20 mg

Oral

N

-

-

10.38

12.21%

9.11

10.38

12.24%

10%

GWAPD

ezetimibe with atorvastatin

Tablet 10 mg-40 mg

Oral

N

-

-

11.23

12.21%

9.86

11.23

12.20%

10%

GWAPD

ezetimibe with atorvastatin

Tablet 10 mg-80 mg

Oral

N

-

-

12.28

12.21%

10.78

12.28

12.21%

10%

GWAPD

fentanyl

Transdermal patch 16.5 mg

Transdermal

Y

N

Y

31.28

25.12%

23.42

31.28

25.13%

10%

GWAPD

flecainide

Tablet containing flecainide acetate 100 mg

Oral

N

-

-

22.49

17.65%

18.52

22.49

17.65%

10%

GWAPD

flecainide

Tablet containing flecainide acetate 50 mg

Oral

N

-

-

18.14

17.65%

14.94

18.14

17.64%

10%

GWAPD

fluticasone propionate with salmeterol

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Inhalation by Mouth

N

-

-

30.5

11.24%

27.07

30.5

11.25%

10%

GWAPD

fluticasone propionate with salmeterol

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Inhalation by Mouth

N

-

-

41.29

11.24%

36.65

41.29

11.24%

10%

GWAPD

fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

Inhalation by Mouth

N

-

-

30.5

11.24%

27.07

30.5

11.25%

10%

GWAPD

fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

Inhalation by Mouth

N

-

-

41.29

11.24%

36.65

41.29

11.24%

10%

GWAPD

fulvestrant

Injection 250 mg in 5 mL pre-filled syringe

Injection

N

-

-

225

13.90%

193.73

225

13.90%

10%

OWAPD

ganirelix

Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe

Injection

N

-

-

32.84

12.42%

28.76

32.84

12.42%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Injection

N

-

-

13.43

34.41%

8.81

10.02

12.08%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

Injection

N

-

-

10.07

34.41%

6.6

7.51

12.12%

10%

GWAPD

hydroxycarbamide

Capsule 500 mg

Oral

N

-

-

36.08

11.53%

31.92

36.08

11.53%

10%

GWAPD

imatinib

Tablet 600 mg (as mesilate)

Oral

Y

N

N

870.98

43.90%

488.62

870.98

43.90%

30%

GWAPD

indapamide

Tablet containing indapamide hemihydrate 1.5 mg (sustained release)

Oral

Y

N

Y

7.17

13.03%

6.24

7.17

12.97%

10%

GWAPD

infliximab

Solution for injection 120 mg in 1 mL pre-filled pen

Injection

Y

N

Y

332.8

24.16%

252.4

332.8

24.16%

10%

GWAPD

ipratropium

Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30

Inhalation

Y

N

Y

7.55

15.05%

6.41

7.55

15.10%

10%

GWAPD

ipratropium

Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30

Inhalation

Y

N

Y

8.92

15.05%

7.58

8.92

15.02%

10%

GWAPD

isotretinoin

Capsule 10 mg

Oral

Y

N

Y

22.02

16.60%

18.36

22.02

16.62%

10%

GWAPD

isotretinoin

Capsule 20 mg

Oral

Y

N

Y

17.16

16.60%

14.31

17.16

16.61%

10%

GWAPD

lacosamide

Tablet 100 mg

Oral

N

-

-

23.09

12.84%

20.13

23.09

12.82%

10%

OWAPD

lacosamide

Tablet 150 mg

Oral

N

-

-

34.63

12.84%

30.18

34.63

12.85%

10%

OWAPD

lacosamide

Tablet 200 mg

Oral

N

-

-

184.69

12.84%

160.98

184.69

12.84%

10%

OWAPD

lacosamide

Tablet 50 mg

Oral

N

-

-

11.54

12.84%

10.06

11.54

12.82%

10%

OWAPD

lincomycin

Injection 600 mg (as hydrochloride monohydrate) in 2 mL

Injection

Y

N

Y

59.78

26.38%

44.01

59.78

26.38%

10%

GWAPD

octreotide

Injection (modified release) 10 mg (as acetate), vial and diluent syringe

Injection

N

-

-

550.71

28.35%

394.58

550.71

28.35%

10%

GWAPD

octreotide

Injection (modified release) 20 mg (as acetate), vial and diluent syringe

Injection

N

-

-

733.16

28.35%

525.31

733.16

28.35%

10%

GWAPD

octreotide

Injection (modified release) 30 mg (as acetate), vial and diluent syringe

Injection

N

-

-

842.51

28.35%

603.66

842.51

28.35%

10%

GWAPD

octreotide

Injection 100 micrograms (as acetate) in 1 mL

Injection

N

-

-

28.95

28.35%

20.74

28.95

28.36%

10%

GWAPD

octreotide

Injection 50 micrograms (as acetate) in 1 mL

Injection

N

-

-

14.49

28.35%

10.38

14.49

28.36%

10%

GWAPD

octreotide

Injection 500 micrograms (as acetate) in 1 mL

Injection

N

-

-

145.02

28.35%

103.91

145.02

28.35%

10%

GWAPD

olmesartan with amlodipine

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)

Oral

N

-

-

7.46

14.41%

6.39

7.46

14.34%

10%

GWAPD

olmesartan with amlodipine

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)

Oral

N

-

-

6.96

14.41%

5.96

6.96

14.37%

10%

GWAPD

paraffin with retinol palmitate

Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g

Application to the eye

N

-

-

5.99

45.24%

3.28

5.99

45.24%

10%

OWAPD

pemetrexed

Powder for I.V. infusion 1 g (as disodium)

Injection

Y

N

Y

91.96

42.27%

53.09

91.96

42.27%

30%

OWAPD

pemetrexed

Powder for I.V. infusion 100 mg (as disodium)

Injection

Y

Y

Y

9.2

42.27%

5.31

7.64

30.50%

30%

OWAPD

pemetrexed

Powder for I.V. infusion 500 mg (as disodium)

Injection

Y

Y

Y

45.98

42.27%

26.54

38.2

30.52%

30%

OWAPD

posaconazole

Tablet (modified release) 100 mg

Oral

N

-

-

201.74

32.29%

136.6

173.44

21.24%

10%

OWAPD

rasagiline

Tablet 1 mg (as mesilate)

Oral

N

-

-

46.18

43.07%

26.29

39.62

33.64%

10%

GWAPD

riluzole

Oral suspension 50 mg per 10 mL, 300 mL

Oral

Y

N

Y

105.13

21.13%

82.92

105.13

21.13%

10%

GWAPD

risedronic acid

Tablet (enteric coated) containing risedronate sodium 35 mg

Oral

Y

N

Y

22.33

14.97%

18.99

22.33

14.96%

10%

GWAPD

risedronic acid

Tablet containing risedronate sodium 150 mg

Oral

Y

N

Y

24.21

14.97%

20.59

24.21

14.95%

10%

GWAPD

risedronic acid

Tablet containing risedronate sodium 35 mg

Oral

Y

N

Y

22.33

14.97%

18.99

22.33

14.96%

10%

GWAPD

sildenafil

Tablet 20 mg (as citrate)

Oral

Y

N

Y

169.35

22.47%

131.3

169.35

22.47%

10%

GWAPD

tacrolimus

Capsule 0.5 mg

Oral

Y

Y

Y

94.81

33.40%

63.14

94.81

33.40%

30%

GWAPD

tacrolimus

Capsule 1 mg

Oral

Y

Y

Y

189.63

33.40%

126.29

189.63

33.40%

30%

GWAPD

tacrolimus

Capsule 1 mg (once daily prolonged release)

Oral

Y

Y

Y

113.78

33.40%

75.78

113.78

33.40%

30%

GWAPD

tacrolimus

Capsule 2 mg

Oral

Y

Y

Y

432.15

33.40%

287.81

432.15

33.40%

30%

GWAPD

tacrolimus

Capsule 5 mg

Oral

Y

Y

Y

473.83

33.40%

315.57

473.83

33.40%

30%

GWAPD

tenofovir

Tablet containing tenofovir disoproxil fumarate 300 mg

Oral

Y

Y

Y

131.36

41.03%

77.46

131.36

41.03%

30%

GWAPD

tenofovir

Tablet containing tenofovir disoproxil maleate 300 mg

Oral

Y

Y

Y

131.36

41.03%

77.46

131.36

41.03%

30%

GWAPD

tenofovir

Tablet containing tenofovir disoproxil phosphate 291 mg

Oral

Y

Y

Y

131.36

41.03%

77.46

131.36

41.03%

30%

GWAPD

tenofovir with emtricitabine and efavirenz

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg and efavirenz 600 mg

Oral

N

-

-

233.8

11.67%

206.52

233.8

11.67%

10%

OWAPD

teriflunomide

Tablet 14 mg

Oral

N

-

-

257.57

41.08%

151.76

210.53

27.92%

10%

OWAPD

tobramycin

Solution for inhalation 300 mg in 5 mL

Inhalation

Y

N

Y

701.02

40.55%

416.76

701.02

40.55%

30%

GWAPD

trastuzumab

Powder for I.V. infusion 440 mg with diluent

Injection

N

-

-

420.77

23.88%

320.29

363

11.77%

10%

OWAPD

trastuzumab

Powder for I.V. infusion 60 mg

Injection

N

-

-

76.32

23.88%

58.09

65.84

11.77%

10%

OWAPD

tropisetron

I.V. injection 5 mg (as hydrochloride) in 5 mL

Injection

Y

N

Y

4.57

44.42%

4

4.57

44.42%

30%

OWAPD

valganciclovir

Tablet 450 mg (as hydrochloride)

Oral

Y

Y

Y

421.13

43.46%

238.11

421.13

43.46%

30%

OWAPD

voriconazole

Tablet 200 mg

Oral

Y

Y

Y

537.86

50.91%

264.04

537.86

50.91%

30%

GWAPD

voriconazole

Tablet 50 mg

Oral

Y

Y

Y

134.47

50.91%

66.01

134.47

50.91%

30%

GWAPD

 

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2023 is available in the 2023 October Combination Flow-on Reductions from Price Disclosure Summary (Excel 16 KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

The indicative prices reports have been replaced by the confirmed prices reports below.

Confirmed prices of brands scheduled for a price disclosure reduction

This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.

The confirmed prices reports for the 2023 October cycle can be downloaded below:

Brand price reductions and savings to patients

This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 October 2023. This information is made available to assist patients with understanding how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reductions reports for the 2023 October cycle can be downloaded below: